Auswahl der wissenschaftlichen Literatur zum Thema „P-PBPK model“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "P-PBPK model" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "P-PBPK model":
Mi, Kun, Shanju Pu, Yixuan Hou, Lei Sun, Kaixiang Zhou, Wenjin Ma, Xiangyue Xu et al. „Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model“. International Journal of Molecular Sciences 23, Nr. 7 (28.03.2022): 3722. http://dx.doi.org/10.3390/ijms23073722.
Jeong, Yoo-Seong, Min-Soo Kim, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung und Kyeong-Ryoon Lee. „Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans“. Pharmaceutics 13, Nr. 6 (29.05.2021): 813. http://dx.doi.org/10.3390/pharmaceutics13060813.
Dallmann, A., P. Mian, P. Annaert, M. Pfister, K. Allegaert und J. van den Anker. „P21 PBPK modeling in pregnancy: achievements, shortcomings and future perspectives“. Archives of Disease in Childhood 104, Nr. 6 (17.05.2019): e25.2-e25. http://dx.doi.org/10.1136/archdischild-2019-esdppp.59.
Nauwelaerts, Nina, Julia Macente, Neel Deferm, Rodolfo Hernandes Bonan, Miao-Chan Huang, Martje Van Neste, David Bibi et al. „Generic Workflow to Predict Medicine Concentrations in Human Milk Using Physiologically-Based Pharmacokinetic (PBPK) Modelling—A Contribution from the ConcePTION Project“. Pharmaceutics 15, Nr. 5 (11.05.2023): 1469. http://dx.doi.org/10.3390/pharmaceutics15051469.
Kovar, Lukas, Christina Schräpel, Dominik Selzer, Yvonne Kohl, Robert Bals, Matthias Schwab und Thorsten Lehr. „Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates“. Pharmaceutics 12, Nr. 6 (23.06.2020): 578. http://dx.doi.org/10.3390/pharmaceutics12060578.
Pilla Reddy, Venkatesh, Adrian J. Fretland, Diansong Zhou, Shringi Sharma, Buyun Chen, Karthick Vishwanathan, Dermot F. McGinnity, Yan Xu und Joseph A. Ware. „Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors“. Cancer Chemotherapy and Pharmacology 88, Nr. 3 (02.06.2021): 451–64. http://dx.doi.org/10.1007/s00280-021-04302-5.
Yang, Yiting, Ping Li, Zexin Zhang, Zhongjian Wang, Li Liu und Xiaodong Liu. „Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes“. International Journal of Molecular Sciences 21, Nr. 19 (24.09.2020): 7023. http://dx.doi.org/10.3390/ijms21197023.
Wills, Kenneth H., Stephen J. Behan, Michael J. Nance, Jessica L. Dawson, Thomas M. Polasek, Ashley M. Hopkins, Madelé van Dyk und Andrew Rowland. „Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure“. Pharmaceutics 14, Nr. 1 (27.12.2021): 47. http://dx.doi.org/10.3390/pharmaceutics14010047.
Kim, Min-Soo, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung und Kyeong-Ryoon Lee. „Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans“. Pharmaceuticals 15, Nr. 6 (03.06.2022): 709. http://dx.doi.org/10.3390/ph15060709.
Bachelet, Delphine, Marc-André Verner, Monica Neri, Émilie Cordina Duverger, Corinne Charlier, Patrick Arveux, Sami Haddad und Pascal Guénel. „Breast Cancer and Exposure to Organochlorines in the CECILE Study: Associations with Plasma Levels Measured at the Time of Diagnosis and Estimated during Adolescence“. International Journal of Environmental Research and Public Health 16, Nr. 2 (18.01.2019): 271. http://dx.doi.org/10.3390/ijerph16020271.
Dissertationen zum Thema "P-PBPK model":
Ali, daoud Yourdasmine. „Une Approche quantitative de l'exposition fœtale au plomb : développement d'un modèle pharmacocinétique basé sur la physiologie de la grossesse (p-PBPK) et application aux données de biosurveillance“. Electronic Thesis or Diss., Paris, AgroParisTech, 2024. http://www.theses.fr/2024AGPT0001.
Lead (Pb) is a highly potent neurotoxin, especially for children. A vast epidemiological literature documents the effects of Pb exposure in young children. Pb can cross the placental barrier to induce early fetal exposure. This prenatal exposure is associated with impaired cognitive function in children, resulting in learning problems, decreased intelligence quotient (IQ) and behavioral problems. For obvious ethical reasons, it is not possible to measure Pb concentrations in the fetus during pregnancy. Consequently, a single measurement obtained from umbilical cord blood at delivery is available to assess prenatal exposure. Thankfully, Pregnancy physiologically based pharmacokinetic (p-PBPK) models can be used to simulate prenatal exposures throughout pregnancy. The aim of this thesis is to provide a tool capable of simulating internal fetal exposures, from incomplete data, such as those obtained during biomonitoring campaigns.A literature search was carried out on the impact of pregnancy on the ADME processes of Pb in both the mother and fetus. This research highlighted an increase in maternal bone turnover (i.e. cycle of formation and resorption) during pregnancy. Indeed, urinary markers of bone formation and resorption linearly increase from the 2nd trimester until the end of pregnancy. Furthermore, data on the kinetic of Pb during pregnancy reveal a distinctive U-shaped trend, an initial phase of decrease during the first 4 months followed by a second phase of increase in maternal blood lead levels. The parameter values modeling bone turnover and placental transfer of Pb were calibrated using literature data. The predictive performance of our p-PBPK model was assessed using paired concentrations of Pb in umbilical cord and maternal blood at delivery, demonstrating satisfactory performance between the model predictions and the observed data. A global sensitivity analysis of the model highlighted à strong influence on fetal exposures from the Pb binding to erythrocytes, Pb accumulation in bones and the partition coefficient in the brain.Pb concentrations measured in the umbilical cord at delivery, from the French Longitudinal Study since Infancy (Elfe), were used in the p-PBPK model to simulate Pb concentrations in the fetal brain. Simulations carried out on the Elfe cohort reveal variations in predicted Pb concentrations in fetal brain over the course of pregnancy. By the end of pregnancy, almost half the fetuses in the Elfe cohort had predicted brain concentrations likely to induce in vitro and ex vivo effects on neurodevelopmental.In conclusion, this thesis highlights the potential of p-PBPK models for assessing prenatal exposure. We have demonstrated the ability of our model to simulate fetal exposure indicators, taking into account the physiological mechanisms essential to Pb toxicokinetics during pregnancy. In the future, this model can be coupled with an effect model such as an Adverse Outcome Pathway (AOP) to help predict the effects of Pb on the neurodevelopment of children
Chow, Edwin C. Y. „Biological Roles of the Vitamin D Receptor in the Regulation of Transporters and Enzymes on Drug Disposition, Including Cytochrome P450 (CYP7A1) on Cholesterol Metabolism“. Thesis, 2012. http://hdl.handle.net/1807/36277.